Robert Pacifici, chief scientific officer of CHDI, said: “As a proven leader in the field of drug discovery, Evotec continues to be an important strategic partner in our search for effective treatments for Huntington’s disease. Their integrated drug discovery capabilities are helping us advance numerous drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years.”
Evotec will provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, screening, computational chemistry, in vitro and in vivo PK and protein crystallography.
Werner Lanthaler, chief executive officer of Evotec, said: “We are delighted that CHDI has chosen to further extend our strategic alliance. We view this as an important step in our work with CHDI to develop novel therapies for huntington’s disease and meet this urgent medical need. At the same time it will allow Evotec to gain further experience in defining the underlying mechanisms of other neurodegenerative diseases.”